Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.

Cancer medicine - 1 Apr 2023

Nukaya Takuhisa, Sumitomo Makoto, Sugihara Eiji, Takeda Mayu, Nohara Sachio, Tanishima Shigeki, Takenaka Masashi, Zennami Kenji, Takahara Kiyoshi, Shiroki Ryoichi, Saya Hideyuki

Abstract excerpt

BACKGROUND: The significance of BRCA alterations has been implicated in the development of metastatic castration-resistant prostate cancer (PC). The details of the frequency and significance of BRCA alterations in localized PC remain unknown. In this study, we investigated the frequency and clinical significance of BRCA alterations in localized PCs using an in-house next-generation sequencer (NGS) system....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Copy Number Variations

Share to Genes, BRCA2

Share to Germ-Line Mutation

Share to Mutation

Share to Prognosis

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36645189
DOI: 10.1002/cam4.5617
PMCID: PMC10134377

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.PMID 36645189Read ↗

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.Semantic proximity Read ↗

DNA alterations in the tumor genome and their associations with clinical outcome in prostate cancer.Semantic proximity Read ↗

Genetic alterations of prostate cancer: in localized and metastatic prostate cancer.Semantic proximity Read ↗

BRCA1 and BRCA2 mutations testing in prostate cancer: Detection in formalin fixed paraffin embedded (FFPE) and blood samplesSemantic proximity Read ↗

Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical QualificationSemantic proximity Read ↗

Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease ProgressionSemantic proximity Read ↗

Somatic DNA copy number alterations and their potential clinical utility for predicting lethal prostate cancer.Semantic proximity Read ↗

Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.Semantic proximity Read ↗

Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencingSemantic proximity Read ↗

Practical Utility of Liquid Biopsy for Evaluating Genomic Alterations in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.Semantic proximity Read ↗

Biallelic BRCA2 Mutations Shape the Somatic Mutational Landscape of Aggressive Prostate Tumors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.